WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
OverviewZen ScorePriceValuationFinancialsForecast
Earnings & RevenueDividendsOwnershipTechnicals
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Top Analysts Upside/Downside
Consensus
Top Analysts Consensus
Analysts
Top Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
ICLR
ICON PLC
$25.59B$309.44$346.4311.95%Strong Buy76.28%31.77%N/AN/A
FONR
FONAR CORP
$108.65M$16.19N/AN/AN/AN/AN/AN/AN/AN/A
IDXX
IDEXX LABORATORIES INC
$41.07B$494.26$584.0018.16%Buy59.73%9.78%N/AN/A
STRR
STAR EQUITY HOLDINGS INC
$13.71M$0.87N/AN/AN/AN/AN/AN/AN/AN/A
RVTY
REVVITY INC
$12.68B$102.68$114.7511.75%Buy84.79%21.89%N/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$12.29B$239.43$264.0010.26%Buy75.12%47.49%N/AN/A
MEDP
MEDPACE HOLDINGS INC
$12.32B$397.56$448.6012.84%Strong Buy513.13%0.10%N/AN/A
NEOG
NEOGEN CORP
$2.68B$12.37$17.0037.43%Hold11.56%526.68%6.20%4.25%
TMO
THERMO FISHER SCIENTIFIC INC
$220.17B$577.39$600.173.94%Strong Buy123.44%57.79%N/AN/A
QGEN
QIAGEN NV
$9.47B$41.52$50.3221.18%Buy54.61%25.27%N/AN/A
ENZ
ENZO BIOCHEM INC
$54.30M$1.06N/AN/AN/AN/AN/AN/AN/AN/A
A
AGILENT TECHNOLOGIES INC
$40.29B$137.49$139.671.58%Buy123.35%35.95%N/AN/A
SHC
SOTERA HEALTH CO
$3.19B$11.27$16.3845.30%Strong Buy44.86%583.33%N/AN/A
DGX
QUEST DIAGNOSTICS INC
$15.28B$137.55$148.337.84%Buy92.63%14.83%N/AN/A
LH
LABORATORY CORP OF AMERICA HOLDINGS
$17.49B$207.94$242.6016.67%Buy55.19%118.89%N/AN/A
CSTL
CASTLE BIOSCIENCES INC
$545.16M$19.86$30.0051.06%Strong Buy38.05%N/AN/AN/A
DHR
DANAHER CORP
$185.48B$250.41$272.558.84%Strong Buy117.55%57.06%N/AN/A
TWST
TWIST BIOSCIENCE CORP
$1.78B$30.75$42.6738.75%Strong Buy315.99%N/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$26.53B$1,235.37$1.18k-4.89%Hold53.63%29.61%N/AN/A
WAT
WATERS CORP
$18.37B$310.25$300.83-3.04%Hold63.45%29.72%N/AN/A
SERA
SERA PROGNOSTICS INC
$325.55M$10.04N/AN/AN/AN/A47.06%N/AN/AN/A
IQV
IQVIA HOLDINGS INC
$43.71B$240.84$260.188.03%Strong Buy116.17%30.17%N/AN/A
XGN
EXAGEN INC
$23.79M$1.38N/AN/AN/AN/A3.33%N/AN/AN/A
PSNL
PERSONALIS INC
$65.66M$1.30$3.50169.23%Buy122.09%N/AN/AN/A
NTRA
NATERA INC
$11.05B$91.50$90.83-0.73%Strong Buy1222.47%N/AN/AN/A
EXAS
EXACT SCIENCES CORP
$11.48B$63.24$92.2045.79%Strong Buy513.49%N/AN/AN/A
PRPO
PRECIPIO INC
$8.38M$5.86N/AN/AN/AN/AN/AN/AN/AN/A
DRIO
DARIOHEALTH CORP
$44.16M$1.50$4.00166.67%Strong Buy134.89%N/AN/AN/A
OLK
OLINK HOLDING AB (PUBL)
$2.79B$22.43$26.0015.92%Hold224.72%N/AN/AN/A
ACRS
ACLARIS THERAPEUTICS INC
$82.98M$1.17$5.00327.35%Buy2-29.88%N/AN/AN/A
NEO
NEOGENOMICS INC
$1.79B$14.03$20.0042.55%Strong Buy610.28%N/AN/AN/A
STIM
NEURONETICS INC
$111.59M$3.75$8.00113.33%Strong Buy110.95%N/AN/AN/A
DMTK
DERMTECH INC
$21.26M$0.61$1.38124.27%Buy329.45%N/A-105.97%-49.69%
GH
GUARDANT HEALTH INC
$2.20B$18.10$36.1499.69%Strong Buy721.15%N/AN/AN/A
OCX
ONCOCYTE CORP
$20.35M$2.46$4.0665.16%Buy4N/AN/A113.17%30.93%
FLGT
FULGENT GENETICS INC
$617.74M$20.74$30.0044.65%Hold25.30%N/AN/AN/A
BNR
BURNING ROCK BIOTECH LTD
$84.07M$0.82N/AN/AN/AN/AN/AN/A-72.92%-53.88%
BGLC
BIONEXUS GENE LAB CORP
$10.51M$0.60N/AN/AN/AN/AN/AN/AN/AN/A
RDNT
RADNET INC
$3.33B$48.67$53.6710.27%Strong Buy38.05%960.00%N/AN/A
LAB
STANDARD BIOTOOLS INC
$702.09M$2.42$3.3839.46%Strong Buy235.69%N/AN/AN/A
APDN
APPLIED DNA SCIENCES INC
$4.06M$0.24$40.0016,636.40%Buy14.14%N/AN/AN/A
PRE
PRENETICS GLOBAL LTD
$58.03M$4.79$9.0087.89%Strong Buy1N/AN/A-3.52%-2.86%
XWEL
XWELL INC
$7.53M$1.80$7.00288.89%Buy1N/AN/AN/AN/A
MDXH
MDXHEALTH SA
$6.73M$2.49$7.50201.20%Strong Buy212.07%N/AN/AN/A
CDNA
CAREDX INC
$413.19M$7.98$15.0087.97%Strong Buy1-4.75%N/AN/AN/A
BDSX
BIODESIX INC
$122.15M$1.26$3.50177.78%Strong Buy132.42%N/AN/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$2.87M$0.26N/AN/AN/AN/AN/AN/AN/AN/A
CHEK
CHECK-CAP LTD
$12.99M$2.22N/AN/AN/AN/AN/AN/AN/AN/A
ME
23ANDME HOLDING CO
$225.52M$0.47$0.470.64%Hold16.26%N/AN/AN/A
ULS
UL SOLUTIONS INC
N/A$33.95N/AN/AN/AN/AN/AN/AN/AN/A
PRPH
PROPHASE LABS INC
$91.31M$5.06$11.00117.39%Buy129.85%N/AN/AN/A
AWH
ASPIRA WOMEN's HEALTH INC
$41.97M$3.40$3.30-2.94%Hold116.89%N/AN/AN/A
OPK
OPKO HEALTH INC
$857.30M$1.23$3.17157.48%Strong Buy32.24%N/AN/AN/A
NOTV
INOTIV INC
$120.44M$4.67$18.25290.79%Strong Buy2-1.09%N/AN/AN/A
VNRX
VOLITIONRX LTD
$65.65M$0.80$3.50337.50%Strong Buy2N/AN/AN/AN/A
MYGN
MYRIAD GENETICS INC
$1.67B$18.63$22.0018.09%Buy48.80%N/AN/AN/A
ISPC
ISPECIMEN INC
$2.53M$0.28N/AN/AN/AN/AN/AN/AN/AN/A
GENE
GENETIC TECHNOLOGIES LTD
$519.38k$2.25N/AN/AN/AN/AN/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$28.21M$2.45N/AN/AN/AN/AN/AN/AN/AN/A
PMD
PSYCHEMEDICS CORP
$15.19M$2.65N/AN/AN/AN/AN/AN/AN/AN/A
ILMN
ILLUMINA INC
$19.52B$122.87$151.0022.89%Buy84.67%N/AN/AN/A
MYNZ
MAINZ BIOMED NV
$19.03M$0.90$3.00233.70%Buy1N/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$14.03M$1.83N/AN/AN/AN/A17.89%N/AN/AN/A
MMA
ALTA GLOBAL GROUP LTD
N/A$3.10N/AN/AN/AN/AN/AN/AN/AN/A
CNTG
CENTOGENE NV
$12.72M$0.46N/AN/AN/AN/AN/AN/AN/AN/A
TTOO
T2 BIOSYSTEMS INC
$15.21M$2.76N/AN/AN/AN/AN/AN/AN/AN/A
1

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the top diagnostic & research stock with a Zen Score of 50, which is 22 points higher than the diagnostic & research industry average of 28. It passed 16 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 49.87% over the past year, overperforming other diagnostic & research stocks by 55 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 11.95% from Icon's current stock price of $309.44.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the second best diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 3.45% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

3. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock lose -1.86% over the past year, overperforming other diagnostic & research stocks by 3 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 18.16% from Idexx Laboratories's current stock price of $494.26.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.08%, which is 2 percentage points higher than the diagnostic & research industry average of 1.35%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.09%, which is 1 percentage points higher than the diagnostic & research industry average of 1.35%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.39%, which is the same as the diagnostic & research industry average of 1.35%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -0.33% in the last day, and up 3.77% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Icon has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Icon's stock has gained 49.87% in the past year. It has overperformed other stocks in the diagnostic & research industry by 55 percentage points.

2. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 8.13% in the past year. It has overperformed other stocks in the diagnostic & research industry by 13 percentage points.

3. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -58.27% in the past year. It has underperformed other stocks in the diagnostic & research industry by -53 percentage points.

Are diagnostic & research stocks a good buy now?

48.94% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 9.65% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.76x.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.